The protein STING plays a crucial role in enabling the immune system to mount a first defense against pathogen infection and tumor growth. It is still unknown how STING exerts its potent anti-cancer effects, and in particular how STING interprets different stimuli and controls distinct downstream signaling responses. Dr. Carina de Oliveira Mann will address this fundamental question by defining the mechanism of differential STING-induced signaling, and determining how synergy between alternative STING responses affects antiviral and antitumor immunity. Dr. de Oliveira Mann’s research aims to identify the components of STING that are responsible for these activities, and potentially discover new avenues through which STING can be used to enhance immune responses against cancer.
Dana-Farber Cancer Institute | All Cancers | 2017 | Philip Kranzusch, Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
This July for Sarcoma Awareness Month, we look at genetics and genomics, new research, and how we’re working toward a future immune to sarcoma.
A follow-up for unanswered questions on cancer genomics and genetic testing with Corrie Painter, Ph.D., and Eliezer Van Allen, M.D.